临床误诊误治2012，Vol.25Issue(2)：41-43,3.DOI:10.3969/j.issn.1002-3429.2012.02.018
沙利度胺联合EP方案对小细胞肺癌患者无进展生存期的影响
Influence of Progression-Free Survival of Therapy with Cisplatin Plus Etposide with Thalidomide in Patients with Small Cell Lung Cancer
摘要
Abstract
Objective To observe the influence of the progression-free survival (PFS) in the small-cell lung cancer (SCLC) patients treated by Cisplatin plus Etposide with Thalidomide. Methods A total of 50 SCLC patients were included and randomly divided into therapeutic alliance group (25 cases) and only chemotherapy group (25 cases). Patients in the therapeutic alliance group were treated with Cisplatin plus Etposide and ThalidomiJe, and patients in the chemotherapy simple group were treated with Cisplatin plus Etposide for a total of 6 cycles, after which PFS of two groups and drug safety were evaluated. Results The 14 patients in the therapeutic alliance group, and the other 11 patients in the chemotherapy simple group were evaluated after the 6-cycle chemotherapy. The PFS was 4. 81 months in the therapeutic alliance group vs. 4. 27 months in the chemotherapy group, and there was no significant difference between the two groups (F =0. 01, P=0. 32). There were no significant changes between the blood routine, liver and renal function and electrocardiogram of the two groups during treatment and observation. Conclusion Treatment by Cisplatin plus Etposide with Thalidomide can not prolong PFS in patients with SCLC.关键词
肺肿瘤/沙利度胺/依托泊苷/顺铂/抗肿瘤联合化疗方案Key words
Lung neoplasm/ Thalidomide/ Etoposide/ Cisplatin/ Antineoplastic combined chemotherapy protocol分类
医药卫生引用本文复制引用
刘非,杨宗宇,孟祥玲,王国华,赵恩锋,史福敏..沙利度胺联合EP方案对小细胞肺癌患者无进展生存期的影响[J].临床误诊误治,2012,25(2):41-43,3.基金项目
沧州市科技局课题(08ZD245) （08ZD245）
